$GILD News Why Apple exemplifies everything that’s

New Post Public Reply Private Reply Replies (0) Message Board

Sep 10, 2014 at 1:03 PM

$GILD News

Why Apple exemplifies everything that’s wrong with Silicon Valley 12:51 p.m. Sept. 9, 2014 - Tim Mullaney
There’s good news for speculative growth traders 2:39 p.m. Sept. 2, 2014 - The Trading Deck
Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore
Surviving "a complex time in the market" 4:57 a.m. Aug. 25, 2014 - MarketWatch
10 S&P 500 companies growing faster than their rivals 3:29 a.m. Aug. 20, 2014 - Philip van Doorn
10 stocks enjoying the biggest increases in earnings estimates 7:27 p.m. Aug. 12, 2014 - Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices 4:17 p.m. Aug. 8, 2014 - blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Gilead trounces estimates on strong Sovaldi sales 4:19 p.m. July 23, 2014 - MarketWatch.com
Gilead trounces estimates for earnings, sales, Sovaldi 4:17 p.m. July 23, 2014 - Russ Britt

Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary 12:00 p.m. Today - Zacks.com
Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog 11:17 a.m. Today - Zacks.com
ERBA Diagnostics (ERB) in Focus: Stock Up 7% - Tale of the Tape 9:39 a.m. Today - Zacks.com
Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog 9:00 a.m. Today - Zacks.com
Stemline Therapeutics (STML) in Focus: Stock Up 12.3% - Tale of the Tape 8:51 a.m. Today - Zacks.com
AstraZeneca Presents Unfavorable Benralizumab Study Data - Analyst Blog 6:35 p.m. Sept. 9, 2014 - Zacks.com
Glaxo (GSK) Updates on Asthma Candidate Mepolizumab - Analyst Blog 6:20 p.m. Sept. 9, 2014 - Zacks.com
Gilead Sciences' (GILD) CEO Presents at Morgan Stanley Healthcare Conference (Transcript) 4:56 p.m. Sept. 9, 2014 - Seeking Alpha
Gilead Sciences (GILD) Presents at Morgan Stanley Global Healthcare Conference (Transcript) 4:56 p.m. Sept. 9, 2014 - Seeking Alpha
Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog 4:50 p.m. Sept. 9, 2014 - Zacks.com
Hospira Down on Legal Blow; Court Allows Generic Precedex - Analyst Blog 4:45 p.m. Sept. 9, 2014 - Zacks.com
Bayer Presents Positive Long-Term Results on Adempas - Analyst Blog 4:25 p.m. Sept. 9, 2014 - Zacks.com
2 Years Of Dividend Growth Investing - 10 Lessons I Have Learned 2:33 p.m. Sept. 9, 2014 - Seeking Alpha
AbbVie Is Betting Big On Infinity Pharmaceuticals But Should You? 12:59 p.m. Sept. 9, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: GE, F, GILD 9:59 a.m. Sept. 9, 2014 - TheStreet.com
Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015 7:44 a.m. Sept. 9, 2014 - 247WallSt.com
Achillion - An Options Strategy For A Potential Acquisition 6:07 p.m. Sept. 8, 2014 - Seeking Alpha
Keryx Falls after Ferric Citrate's Approval with Warnings - Analyst Blog 6:05 p.m. Sept. 8, 2014 - Zacks.com
OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog 6:00 p.m. Sept. 8, 2014 - Zacks.com
Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog 5:35 p.m. Sept. 8, 2014 - Zacks.com

Critical Alerts For Gilead Sciences, Incyte Corp., Infinera Corporation, Ford and Pixelworks Released By InvestorsObserver 9:31 a.m. Sept. 9, 2014 - PR Newswire - PRF
Global Hepatitis C Market 2014-2018 9:58 p.m. Sept. 8, 2014 - PR Newswire - PRF
Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher 9:20 a.m. Sept. 4, 2014 - PR Newswire - PRF
Gilead Sciences to Present at Two Upcoming Investor Conferences in September 5:00 p.m. Sept. 3, 2014 - BusinessWire - BZX
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay 9:05 a.m. Sept. 3, 2014 - PR Newswire - PRF
Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard 9:10 a.m. Aug. 27, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Disney, Starbucks, Rockwell Medical and AT&T Released By InvestorsObserver 9:31 a.m. Aug. 21, 2014 - PR Newswire - PRF
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana 9:20 a.m. Aug. 19, 2014 - PR Newswire - PRF
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver 9:31 a.m. Aug. 4, 2014 - PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 11:49 a.m. July 23, 2014 - BusinessWire - BZX
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 5:00 p.m. July 16, 2014 - BusinessWire - BZX
Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver 9:31 a.m. July 14, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

QuickFi Nabs Top Finovate Award for Fourth Time

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

Sustainability Investments: $17 Trillion Wager Faces Divergence

Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...

Jari Spirits Set to Shake Up U.S. Market After Big Wins

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

Oil Markets Shift Focus: Pipelines Trump Drilling

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

2026 Buy-Side Index Reveals State Market Variance

Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...

NYSE Reflects on 9/11: Honoring Lives and Legacy

A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...

Supply Maverick Simplifies Global Shipping Processes

Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...

Fermi's Founder Pushes for Board Overhaul: What's Next?

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

Lick the Plate Hits 2,000 Shows with Clown Band

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

Americas Cardroom's Poker Series Hits $7.2M Haul

Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...